Archives

MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

B – Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study – Japan Phase 3 results strengthen CARTISTEM’s®… Login to continue reading Login…

Read MoreMEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

Origin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET

B BEIJING, May 14, 2026 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), a leading Chinese agricultural technology company, will announce its… Login to continue reading Login…

Read MoreOrigin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET

CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

B Financing to support advancement of CREATE’s repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its… Login to continue reading Login…

Read MoreCREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology